Fuhrman Alan 4

What Happened Alan Fuhrman, Chief Financial Officer of Tyra Biosciences (TYRA), acquired 1,376 shares on March 13, 2026 at $9.13 per share, for a total value of $12,562. The filing reports an acquisition (code A) rather than a sale, indicating these were shares received/purchased rather than disposed of.

Key Details

• Transaction date: 2026-03-13; Price: $9.13 per share; Total value: $12,562.
• Transaction type: Acquisition under Issuer's 2021 Employee Stock Purchase Plan (ESPP) — footnote F1.
• Shares owned after transaction: Not disclosed in this Form 4.
• Filing: Reported on Form 4 filed 2026-03-17. This appears timely (filed within the standard two-business-day window).
• Transaction code: A = Grant/award/other acquisition.

Context This was an ESPP acquisition, a routine employee purchase mechanism that often buys shares at a discount through payroll deductions or plan elections. Such purchases are generally viewed as routine compensation/benefit activity rather than an explicit market signal, though purchases can be interpreted as modestly bullish. The transaction is small in dollar terms (~$12.6k) and factual — no motivation is implied.